GED Capital
Overview
GED Capital is an independent asset manager founded in 1996 that operates in the middle-market segment . It manages over €1 billion through different Private Equity, Infrastructure and Venture Capital vehicles . GED Capital has a universe of over 800 domestic and foreign investors, including mainly pension funds, funds of funds, insurance companies, family offices and financial institutions . GED Capital stands out for its diversified multi-asset strategy across three verticals: Private Equity, with Buyout, Healthcare and Secondaries strategies, Infrastructure with both private and public investment vehicles with European Structural and Investment Funds and Venture Capital, with funds in Spain and Portugal, focusing its investment on startups and entrepreneurs that promote technological and digital progress .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Kushki | Jun 2021 | Series B | Co-investor |
| Quibim | Jan 2025 | Series A | Lead |
| Highlight Therapeutics | Sep 2025 | Growth Equity | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is GED Capital based?
GED Capital is headquartered in Madrid, Madrid, Spain.
When was GED Capital founded?
GED Capital was founded in 1996.
How many portfolio companies does GED Capital have?
GED Capital has 3 portfolio companies in Caplight's dataset.
What are some companies in GED Capital's portfolio?
Portfolio companies visible on Caplight include Kushki, Quibim, Highlight Therapeutics.
What was GED Capital's most recent investment shown here?
GED Capital's most recent investment in this portfolio sample was in Highlight Therapeutics in 2025.
What sectors does GED Capital focus on?
GED Capital focuses on Healthcare & Life Sciences, FinTech, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Enterprise Software.
What company stages does GED Capital focus on?
Stage focus information for GED Capital is not publicly available.
What is GED Capital's AUM?
GED Capital's assets under management are estimated between $1.0B and $10.0B.